A snapshot of polymyxin use around the world South America

Size: px
Start display at page:

Download "A snapshot of polymyxin use around the world South America"

Transcription

1 A snapshot of polymyxin use around the world South America Alexandre P. Zavascki Infectious Diseases Service, Hospital de Clínicas de Porto Alegre Medical School, Federal University of Rio Grande do Sul - Brazil 1

2 A snapshot of polymyxin use of polymyxins in South America Focus on Brazil 1. Is the polymyxin in your setting used empirically or as definitive therapy when susceptibilities are known? 2. If empiric therapy, in what type of conditions is it used? 3. If definitive therapy, for what organisms and in what conditions? What are the mechanisms leading to bacterial resistance (if known)? 4. Is the polymyxin used in combination or as monotherapy? If combination therapy, combined with what? 5. What dosing regimen of polymyxin is typically used? Is a loading dose given? 6. Is there local experience on toxicity - its extent and risk factors for it? 7. What is the typical duration of polymyxin use? 8. What is the typical outcome of polymyxin use in your setting? 9. Is resistance to the polymyxins observed in your setting? 2

3 Many reports of carbapenemases in South American countries Few data on polymyxins use, except Brazil VIM KPC OXA NDM OXA KPC VIM KPC OXA KPC VIM KPC OXA NDM VIM NDM 3

4 Colistin Argentina Chile and Bolivia Polymyxin B Colombia 4

5 Brazil Largest Country Polymyxin B 60 80% Colistin % 5

6 Polymyxins Use in Brazil Mid 90 s Small outbreaks CRPA / CRAB 3 major epidemics large scale polymyxins 2000: SPM-1 MbL- P. aeruginosa 2004: OXA-23-producing A. baumannii 2009: KPC-2-producing Enterobacteiraceae Gales et al. J Antimicrob Chemother Zavascki et al. J Antimicrob Chemother Dalla-Costa et al. J Clin Microbiol Prates et al. Epidemiol Infect Monteiro et al. Antimicrob Agents Chemother Zavascki et al. Int J Infect Dis

7 1. Polymyxins Empirically or as definitive therapy? Definitive, when susceptibilities were known ~2004 Epidemics of OXA-23 A. baumannii empirically in many hospitals Emergence of KPC-2 Enterobacteriaceae empirically in most hospitals 7

8 First empirical prescriptions after failure with carbapenems more common conditions After Empiric therapy Which conditions is it used? Empirical use regardless the previous use of any antimicrobial agent 8

9 3. Organisms and conditions? SPM-1 (IMP-1)- P. aeruginosa Many OXA-23 (OXA-143)- A. baumannii - HAP / VAP KPC-2 Enterobacteriaceae - UTI Resistance mechanisms not routinely evaluated 9

10 4. Polymyxins Combination or monotherapy? Until the emergence of KPC-2 monotherapy Combination therapy more frequently almost always for severe infections High dose / extended infusion carbapenem Tigecycline (200mg LD 100mg bid) Aminoglycoside Three drugs 10

11 First years fear of toxicity Low doses prescribed Better clinical experience and understanding of toxicity + Improved knowledge of PK and PK/PD Highest recommended doses Loading doses still not commonly given More common for CMS 5. Polymyxins Dosing regimens 11

12 Polymyxin B: mg/kg/day 12h Colistin: Garonzik et al.: 6MU to 9MU CMS 8h (12MU/day) 5. Polymyxins Dosing regimens 12

13 ~ 50% some degree of renal dysfunction ~ 1/4 Mild (>50% <100% increase creatinine level) ~ 1/2 Moderate (> 100%) ~ 1/4 (10% of all) Severe (RRT) Main risk factor Daily Dose, but not cumulative dose Highly variable! 6. Toxicity extent and risk factors Less frequent? Elias et al. J Antimicrob Chemother

14 Toxicity extent and risk factors CMS (n=36) Polymyxin B (n=96) AKI - Any grade 15 42% 23 24% AKIN % 13 14% AKIN % 9 9% AKIN % 1 1% Dialysis 2 6% 1 1% Tuon et al. Unpublished data 14

15 7. Duration of polymyxin treatment 14 days most infections Pneumonia BSI 7 days non-complicated UTI 15

16 First years very poor outcomes Delay in initiation? Low doses? Monotherapy? 8. Polymyxins Outcomes Outcomes improving in latter years? Mortality rates STILL HIGH in critical patients 16

17 : 276 patients 218 (79%) ICU pts Polymyxins Outcomes Mortality % <150 mg mg 200 mg Elias et al. J Antimicrob Chemother P =

18 polymyxin B VAP A. baumannii or P. aeruginosa monotherapy 30-day mortality = 53% Polymyxins Outcomes Polymyxin B 30-day mortality = 54% CMS 30-day mortality = 50% Rigatto et al. Infection Tuon et al. Unpublished data. 18

19 9. Is resistance to the polymyxins observed in your setting? Resistance rates highly variable low 5% of CR GNB Increasing in some centers, especially in CRE 10-15% 19

20 Concluding Remarks Very common drugs in most Brazilian institutions No perspective for decreasing polymyxins use NDM-1 detected in Brazil 20

21 Afonso Barth - BR Alan Forrest - EU Cornelia Landersdorfer - AU Ana Gales - BR Jian Li - AU Marines Martinho - BR The National Council for Scientific and Technological Development (CNPq) Acknowledgements Roger Nation - AU Vanessa Ribeiro - BR Jaime Rocha - BR Jorge Sampaio - BR Ana Sandri - BR Felipe Tuon - BR Federal University of Rio Grande do Sul Hospital de Clínicas de Porto Alegre 21

Fighting MDR Pathogens in the ICU

Fighting MDR Pathogens in the ICU Fighting MDR Pathogens in the ICU Dr. Murat Akova Hacettepe University School of Medicine, Department of Infectious Diseases, Ankara, Turkey 1 50.000 deaths each year in US and Europe due to antimicrobial

More information

Mono- versus Bitherapy for Management of HAP/VAP in the ICU

Mono- versus Bitherapy for Management of HAP/VAP in the ICU Mono- versus Bitherapy for Management of HAP/VAP in the ICU Jean Chastre, www.reamedpitie.com Conflicts of interest: Consulting or Lecture fees: Nektar-Bayer, Pfizer, Brahms, Sanofi- Aventis, Janssen-Cilag,

More information

Outline. Antimicrobial resistance. Antimicrobial resistance in gram negative bacilli. % susceptibility 7/11/2010

Outline. Antimicrobial resistance. Antimicrobial resistance in gram negative bacilli. % susceptibility 7/11/2010 Multi-Drug Resistant Organisms Is Combination Therapy the Way to Go? Sutthiporn Pattharachayakul, PharmD Prince of Songkhla University, Thailand Outline Prevalence of anti-microbial resistance in Acinetobacter

More information

ETX2514SUL (sulbactam/etx2514) for the treatment of Acinetobacter baumannii infections

ETX2514SUL (sulbactam/etx2514) for the treatment of Acinetobacter baumannii infections ETX2514SUL (sulbactam/etx2514) for the treatment of Acinetobacter baumannii infections Robin Isaacs Chief Medical Officer, Entasis Therapeutics Dr. Isaacs is a full-time employee of Entasis Therapeutics.

More information

Update on Resistance and Epidemiology of Nosocomial Respiratory Pathogens in Asia. Po-Ren Hsueh. National Taiwan University Hospital

Update on Resistance and Epidemiology of Nosocomial Respiratory Pathogens in Asia. Po-Ren Hsueh. National Taiwan University Hospital Update on Resistance and Epidemiology of Nosocomial Respiratory Pathogens in Asia Po-Ren Hsueh National Taiwan University Hospital Ventilator-associated Pneumonia Microbiological Report Sputum from a

More information

4/3/2017 CLINICAL PEARLS: UPDATES IN THE MANAGEMENT OF NOSOCOMIAL PNEUMONIA DISCLOSURE LEARNING OBJECTIVES

4/3/2017 CLINICAL PEARLS: UPDATES IN THE MANAGEMENT OF NOSOCOMIAL PNEUMONIA DISCLOSURE LEARNING OBJECTIVES CLINICAL PEARLS: UPDATES IN THE MANAGEMENT OF NOSOCOMIAL PNEUMONIA BILLIE BARTEL, PHARMD, BCCCP APRIL 7 TH, 2017 DISCLOSURE I have had no financial relationship over the past 12 months with any commercial

More information

Appropriate antimicrobial therapy in HAP: What does this mean?

Appropriate antimicrobial therapy in HAP: What does this mean? Appropriate antimicrobial therapy in HAP: What does this mean? Jaehee Lee, M.D. Kyungpook National University Hospital, Korea KNUH since 1907 Presentation outline Empiric antimicrobial choice: right spectrum,

More information

Dissecting the epidemiology of resistant Enterobacteriaceae and non-fermenters

Dissecting the epidemiology of resistant Enterobacteriaceae and non-fermenters Dissecting the epidemiology of resistant Enterobacteriaceae and non-fermenters Jon Otter, PhD Centre for Clinical Infection and Diagnostics Research (CIDR), King's College London & Guy's and St. Thomas'

More information

Witchcraft for Gram negatives

Witchcraft for Gram negatives Witchcraft for Gram negatives Dr Subramanian S MD DNB MNAMS AB (Medicine, Infect Dis) Infectious Diseases Consultant Global Health City, Chennai www.asksubra.com Drug resistance follows the drug like a

More information

Other β-lactamase Inhibitor (BLI) Combinations: Focus on VNRX-5133, WCK 5222 and ETX2514SUL

Other β-lactamase Inhibitor (BLI) Combinations: Focus on VNRX-5133, WCK 5222 and ETX2514SUL Other β-lactamase Inhibitor (BLI) Combinations: Focus on VNRX-5133, WCK 5222 and ETX2514SUL David P. Nicolau, PharmD, FCCP, FIDSA Director, Center for Anti-Infective Research and Development Hartford Hospital

More information

Rise of Resistance: From MRSA to CRE

Rise of Resistance: From MRSA to CRE Rise of Resistance: From MRSA to CRE Paul D. Holtom, MD Professor of Medicine and Orthopaedics USC Keck School of Medicine SUPERBUGS (AKA MDROs) MRSA Methicillin-resistant S. aureus Evolution of Drug Resistance

More information

Nosocomial Infections: What Are the Unmet Needs

Nosocomial Infections: What Are the Unmet Needs Nosocomial Infections: What Are the Unmet Needs Jean Chastre, MD Service de Réanimation Médicale Hôpital Pitié-Salpêtrière, AP-HP, Université Pierre et Marie Curie, Paris 6, France www.reamedpitie.com

More information

Antimicrobial Stewardship

Antimicrobial Stewardship Antimicrobial Stewardship Background Why Antimicrobial Stewardship 30-50% of antibiotic use in hospitals are unnecessary or inappropriate Appropriate antimicrobial use is a medication-safety and patient-safety

More information

Updates on the Management of Hospital Acquired Infections and Resistant Organisms

Updates on the Management of Hospital Acquired Infections and Resistant Organisms Updates on the Management of Hospital Acquired Infections and Resistant Organisms Kaitlin McGinn, PharmD Assistant Clinical Professor, Critical Care Auburn University, Harrison School of Pharmacy November

More information

Updates on the Management of Hospital Acquired Infections and Resistant Organisms

Updates on the Management of Hospital Acquired Infections and Resistant Organisms Updates on the Management of Hospital Acquired Infections and Resistant Organisms Conflict of Interest I, Kaitlin McGinn, have no actual or potential conflict of interest in relation to this program. Kaitlin

More information

High-Risk MDR clones news in treatment

High-Risk MDR clones news in treatment Ferrara, 20 giugno 2013 High-Risk MDR clones news in treatment Pierluigi Viale Clinica di Malattie Infettive Policlinico S. Orsola Malpighi Characteristics and determinants of outcome of hospital-acquired

More information

Breaking the Ring. β-lactamases and the Great Arms Race. Bryce M Kayhart, PharmD, BCPS PGY2 Pharmacotherapy Resident Mayo Clinic - Rochester

Breaking the Ring. β-lactamases and the Great Arms Race. Bryce M Kayhart, PharmD, BCPS PGY2 Pharmacotherapy Resident Mayo Clinic - Rochester Breaking the Ring β-lactamases and the Great Arms Race Bryce M Kayhart, PharmD, BCPS PGY2 Pharmacotherapy Resident Mayo Clinic - Rochester 2015 MFMER slide-1 Disclosures I have no relevant financial relationships

More information

Difficult to Treat Bacterial Infections: Have we reached a Dead End?

Difficult to Treat Bacterial Infections: Have we reached a Dead End? Difficult to Treat Bacterial Infections: Have we reached a Dead End? Dr. George M. Varghese MD, DNB, DTMH, FRCP, FIDSA Department of Infectious Diseases Christian Medical College, Vellore, India Outline

More information

OPTIMIZATION OF PK/PD OF ANTIBIOTICS FOR RESISTANT GRAM-NEGATIVE ORGANISMS

OPTIMIZATION OF PK/PD OF ANTIBIOTICS FOR RESISTANT GRAM-NEGATIVE ORGANISMS HTIDE CONFERENCE 2018 OPTIMIZATION OF PK/PD OF ANTIBIOTICS FOR RESISTANT GRAM-NEGATIVE ORGANISMS FEDERICO PEA INSTITUTE OF CLINICAL PHARMACOLOGY DEPARTMENT OF MEDICINE, UNIVERSITY OF UDINE, ITALY SANTA

More information

* gender factor (male=1, female=0.85)

* gender factor (male=1, female=0.85) Usual Doses of Antimicrobials Typically Not Requiring Renal Adjustment Azithromycin 250 500 mg Q24 *Amphotericin B 1 3-5 mg/kg Q24 Clindamycin 600 900 mg Q8 Liposomal (Ambisome ) Doxycycline 100 mg Q12

More information

Florida Health Care Association District 2 January 13, 2015 A.C. Burke, MA, CIC

Florida Health Care Association District 2 January 13, 2015 A.C. Burke, MA, CIC Florida Health Care Association District 2 January 13, 2015 A.C. Burke, MA, CIC 11/20/2014 1 To describe carbapenem-resistant Enterobacteriaceae. To identify laboratory detection standards for carbapenem-resistant

More information

CARBAPENEM RESISTANT ENTEROBACTERIACEAE (KPC CRE)

CARBAPENEM RESISTANT ENTEROBACTERIACEAE (KPC CRE) CARBAPENEM RESISTANT ENTEROBACTERIACEAE (KPC CRE) Bartsch SM et al. Potential economic burden of carbapenem-resistent Enterobacteriaceae (CRE) in the United States. Clin Microbiol Infect 2017;23(1):48e9-e16.

More information

DR. MICHAEL A. BORG DIRECTOR OF INFECTION PREVENTION & CONTROL MATER DEI HOSPITAL - MALTA

DR. MICHAEL A. BORG DIRECTOR OF INFECTION PREVENTION & CONTROL MATER DEI HOSPITAL - MALTA DR. MICHAEL A. BORG DIRECTOR OF INFECTION PREVENTION & CONTROL MATER DEI HOSPITAL - MALTA The good old days The dread (of) infections that used to rage through the whole communities is muted Their retreat

More information

Antimicrobial Cycling. Donald E Low University of Toronto

Antimicrobial Cycling. Donald E Low University of Toronto Antimicrobial Cycling Donald E Low University of Toronto Bad Bugs, No Drugs 1 The Antimicrobial Availability Task Force of the IDSA 1 identified as particularly problematic pathogens A. baumannii and

More information

Presenter: Ombeva Malande. Red Cross Children's Hospital Paed ID /University of Cape Town Friday 6 November 2015: Session:- Paediatric ID Update

Presenter: Ombeva Malande. Red Cross Children's Hospital Paed ID /University of Cape Town Friday 6 November 2015: Session:- Paediatric ID Update Emergence of invasive Carbapenem Resistant Enterobacteriaceae CRE infection at RCWMCH Ombeva Oliver Malande, Annerie du Plessis, Colleen Bamford, Brian Eley Presenter: Ombeva Malande Red Cross Children's

More information

HEALTHCARE-ACQUIRED INFECTIONS AND ANTIMICROBIAL RESISTANCE

HEALTHCARE-ACQUIRED INFECTIONS AND ANTIMICROBIAL RESISTANCE Universidade de São Paulo Departamento de Moléstias Infecciosas e Parasitárias HEALTHCARE-ACQUIRED INFECTIONS AND ANTIMICROBIAL RESISTANCE Anna S. Levin 4 main lines! Epidemiology of HAS and resistance!

More information

Antimicrobial stewardship in managing septic patients

Antimicrobial stewardship in managing septic patients Antimicrobial stewardship in managing septic patients November 11, 2017 Samuel L. Aitken, PharmD, BCPS (AQ-ID) Clinical Pharmacy Specialist, Infectious Diseases slaitken@mdanderson.org Conflict of interest

More information

Infection Control of Emerging Diseases

Infection Control of Emerging Diseases 2016 EPS Training Event Martin E. Evans, MD Director, VHA MDRO Program National Infectious Diseases Service Lexington, KY & Cincinnati, OH Infection Control of Emerging Diseases 2016 EPS Training Event

More information

Carbapenem-Resistance in Gram-Negative Bacilli and Intravenous Minocycline: An Antimicrobial Stewardship Approach at the Detroit Medical Center

Carbapenem-Resistance in Gram-Negative Bacilli and Intravenous Minocycline: An Antimicrobial Stewardship Approach at the Detroit Medical Center SUPPLEMENT ARTICLE Carbapenem-Resistance in Gram-Negative Bacilli and Intravenous : An Antimicrobial Stewardship Approach at the Detroit Medical Center Jason M. Pogue, 1,2 Anupama Neelakanta, 2 Ryan P.

More information

Antibiotic Updates: Part II

Antibiotic Updates: Part II Antibiotic Updates: Part II Fredrick M. Abrahamian, DO, FACEP, FIDSA Health Sciences Clinical Professor of Emergency Medicine David Geffen School of Medicine at UCLA Los Angeles, California Financial Disclosures

More information

2017 Introduction to Infectious Diseases Clinical Seminar Saturday 30th September - Sunday 1st October 2017 Hotel Grand Chancellor Hobart, Tasmania

2017 Introduction to Infectious Diseases Clinical Seminar Saturday 30th September - Sunday 1st October 2017 Hotel Grand Chancellor Hobart, Tasmania 2017 Introduction to Infectious Diseases Clinical Seminar Saturday 30th September - Sunday 1st October 2017 Hotel Grand Chancellor Hobart, Tasmania Day 1: Saturday 30 th September 2017 09:00 09:20 Registration

More information

Any role for old antibiotics? Assoc Prof George Dimopoulos MD, PhD, FCCP, FCCM, FECMM

Any role for old antibiotics? Assoc Prof George Dimopoulos MD, PhD, FCCP, FCCM, FECMM Assoc Prof George Dimopoulos MD, PhD, FCCP, FCCM, FECMM Department of Critical Care, University Hospital ATTIKON National and Kapodistrian University of Athens, Medical School gdimop@med.uoa.gr Faculty

More information

The Challenges of Antimicrobial Resistance in Brazil

The Challenges of Antimicrobial Resistance in Brazil ANTIMICROBIAL RESISTANCE George M. Eliopoulos, Section Editor INVITED ARTICLE The Challenges of Antimicrobial Resistance in Brazil Flávia Rossi Pathology Department, DLC_LIM 03, Hospital das Clínicas da

More information

Intrinsic, implied and default resistance

Intrinsic, implied and default resistance Appendix A Intrinsic, implied and default resistance Magiorakos et al. [1] and CLSI [2] are our primary sources of information on intrinsic resistance. Sanford et al. [3] and Gilbert et al. [4] have been

More information

Summary of unmet need guidance and statistical challenges

Summary of unmet need guidance and statistical challenges Summary of unmet need guidance and statistical challenges Daniel B. Rubin, PhD Statistical Reviewer Division of Biometrics IV Office of Biostatistics, CDER, FDA 1 Disclaimer This presentation reflects

More information

What does multiresistance actually mean? Yohei Doi, MD, PhD University of Pittsburgh

What does multiresistance actually mean? Yohei Doi, MD, PhD University of Pittsburgh What does multiresistance actually mean? Yohei Doi, MD, PhD University of Pittsburgh Disclosures Merck Research grant Clinical context of multiresistance Resistance to more classes of agents Less options

More information

2017 Introduction to Infectious Diseases Clinical Seminar Saturday 30th September - Sunday 1st October 2017 Hotel Grand Chancellor Hobart, Tasmania

2017 Introduction to Infectious Diseases Clinical Seminar Saturday 30th September - Sunday 1st October 2017 Hotel Grand Chancellor Hobart, Tasmania 2017 Introduction to Infectious Diseases Clinical Seminar Saturday 30th September - Sunday 1st October 2017 Hotel Grand Chancellor Hobart, Tasmania Day 1: Saturday 30 th September 2017 Time Topic/Activity

More information

MDR Acinetobacter baumannii. Has the post antibiotic era arrived? Dr. Michael A. Borg Infection Control Dept Mater Dei Hospital Malta

MDR Acinetobacter baumannii. Has the post antibiotic era arrived? Dr. Michael A. Borg Infection Control Dept Mater Dei Hospital Malta MDR Acinetobacter baumannii Has the post antibiotic era arrived? Dr. Michael A. Borg Infection Control Dept Mater Dei Hospital Malta 1 The Armageddon recipe Transmissible organism with prolonged environmental

More information

Sustaining an Antimicrobial Stewardship

Sustaining an Antimicrobial Stewardship Sustaining an Antimicrobial Stewardship Much needless expense, untoward effect, harm and disappointment can be prevented by better judgment in the use of antimicrobials Whitney A. Jones, PharmD Antimicrobial

More information

Successful stewardship in hospital settings

Successful stewardship in hospital settings Successful stewardship in hospital settings Pr Charles-Edouard Luyt Service de Réanimation Institut de Cardiologie Groupe Hospitalier Pitié-Salpêtrière Université Pierre et Marie Curie, Paris 6 www.reamedpitie.com

More information

Antibiotic Resistance. Antibiotic Resistance: A Growing Concern. Antibiotic resistance is not new 3/21/2011

Antibiotic Resistance. Antibiotic Resistance: A Growing Concern. Antibiotic resistance is not new 3/21/2011 Antibiotic Resistance Antibiotic Resistance: A Growing Concern Judy Ptak RN MSN Infection Prevention Practitioner Dartmouth-Hitchcock Medical Center Lebanon, NH Occurs when a microorganism fails to respond

More information

The International Collaborative Conference in Clinical Microbiology & Infectious Diseases

The International Collaborative Conference in Clinical Microbiology & Infectious Diseases The International Collaborative Conference in Clinical Microbiology & Infectious Diseases PLUS: Antimicrobial stewardship in hospitals: Improving outcomes through better education and implementation of

More information

Carbapenemase-Producing Enterobacteriaceae (CPE)

Carbapenemase-Producing Enterobacteriaceae (CPE) Carbapenemase-Producing Enterobacteriaceae (CPE) September 21, 2017 Maryam Khan Peel Public Health Madeleine Ashcroft Public Health Ontario Objectives Differentiate the acronyms related to CPE (CPE,CPO,CRE,CRO)

More information

PRACTIC GUIDELINES for APPROPRIATE ANTIBIOTICS USE

PRACTIC GUIDELINES for APPROPRIATE ANTIBIOTICS USE PRACTIC GUIDELINES for APPROPRIATE ANTIBIOTICS USE Global Alliance for Infection in Surgery World Society of Emergency Surgery (WSES) and not only!! Aims - 1 Rationalize the risk of antibiotics overuse

More information

Antibiotic Stewardship in the Hospital Setting

Antibiotic Stewardship in the Hospital Setting Antibiotic Stewardship in the Hospital Setting G. Evans, MD FRCPC Medical Director, Infection Prevention & Control Kingston General Hospital & Hotel Dieu Hospital EOPIC September 26, 2012 Stewardship stew-ard-ship

More information

Pharmacodynamics as an Approach to Optimizing Therapy Against Problem Pathogens

Pharmacodynamics as an Approach to Optimizing Therapy Against Problem Pathogens Pharmacodynamics as an Approach to Optimizing Therapy Against Problem Pathogens Jared L. Crandon, Pharm.D., BCPS Associate Director, Clinical and Experimental Pharmacology Center for Anti-Infective Research

More information

Multi-drug resistant microorganisms

Multi-drug resistant microorganisms Multi-drug resistant microorganisms Arzu TOPELI Director of MICU Hacettepe University Faculty of Medicine, Ankara-Turkey Council Member of WFSICCM Deaths in the US declined by 220 per 100,000 with the

More information

Jump Starting Antimicrobial Stewardship

Jump Starting Antimicrobial Stewardship Jump Starting Antimicrobial Stewardship Amanda C. Hansen, PharmD Pharmacy Operations Manager Carilion Roanoke Memorial Hospital Roanoke, Virginia March 16, 2011 Objectives Discuss guidelines for developing

More information

Antimicrobial Stewardship Esperienza Torinese

Antimicrobial Stewardship Esperienza Torinese Pisa 15 Novembre 2016 Antimicrobial Stewardship Esperienza Torinese Francesco G. De Rosa Dipartimento di Scienze Mediche Università di Torino Antimicrobial Stewardship First introduced by Dale Gerding

More information

Building a Better Mousetrap for Nosocomial Drug-resistant Bacteria: use of available resources to optimize the antimicrobial strategy

Building a Better Mousetrap for Nosocomial Drug-resistant Bacteria: use of available resources to optimize the antimicrobial strategy Building a Better Mousetrap for Nosocomial Drug-resistant Bacteria: use of available resources to optimize the antimicrobial strategy Leonardo Pagani MD Director Unit for Hospital Antimicrobial Chemotherapy

More information

10/9/2012. Unprecedented success of antibiotics in 1960s. Infectious diseases are #1 cause of mortality worldwide

10/9/2012. Unprecedented success of antibiotics in 1960s. Infectious diseases are #1 cause of mortality worldwide I have no conflicts of interest in relation to this program Whitney Jones, PharmD Antimicrobial Stewardship Pharmacist Vanderbilt University Medical Center October 25, 2012 Understand the epidemiology

More information

OAHHS Webinar. Christopher D. Pfeiffer, MD, MHS April 30, 2014

OAHHS Webinar. Christopher D. Pfeiffer, MD, MHS April 30, 2014 OAHHS Webinar Christopher D. Pfeiffer, MD, MHS April 30, 2014 Learning Objectives / Outline 1. Understand: What are CRE? Which CRE are most important? Why? 2. Learn about CRE epidemiology, nationally and

More information

Inappropriate Use of Antibiotics and Clostridium difficile Infection. Jocelyn Srigley, MD, FRCPC November 1, 2012

Inappropriate Use of Antibiotics and Clostridium difficile Infection. Jocelyn Srigley, MD, FRCPC November 1, 2012 Inappropriate Use of Antibiotics and Clostridium difficile Infection Jocelyn Srigley, MD, FRCPC November 1, 2012 Financial Disclosures } No conflicts of interest } The study was supported by a Hamilton

More information

Hospital ID: 831. Bourguiba Hospital. Tertiary hospital

Hospital ID: 831. Bourguiba Hospital. Tertiary hospital Global Point Prevalence Survey of Antimicrobial Consumption and Resistance in hospitals worldwide Hospital ID: 831 Habib Bourguiba Hospital Tertiary hospital Tunisia Point Prevalence Survey Habib 2017

More information

New Opportunities for Microbiology Labs to Add Value to Antimicrobial Stewardship Programs

New Opportunities for Microbiology Labs to Add Value to Antimicrobial Stewardship Programs New Opportunities for Microbiology Labs to Add Value to Antimicrobial Stewardship Programs Patrick R. Murray, PhD Senior Director, WW Scientific Affairs 2017 BD. BD, the BD Logo and all other trademarks

More information

OPTIMIZING ANTIMICROBIAL PHARMACODYNAMICS: A GUIDE FOR YOUR STEWARDSHIP PROGRAM

OPTIMIZING ANTIMICROBIAL PHARMACODYNAMICS: A GUIDE FOR YOUR STEWARDSHIP PROGRAM Document downloaded from http://www.elsevier.es, day 06/04/2018. This copy is for personal use. Any transmission of this document by any media [REV. or MED. format is CLIN. strictly CONDES prohibited.

More information

ETX2514: Responding to the global threat of nosocomial multidrug and extremely drug resistant Gram-negative pathogens

ETX2514: Responding to the global threat of nosocomial multidrug and extremely drug resistant Gram-negative pathogens ETX2514: Responding to the global threat of nosocomial multidrug and extremely drug resistant Gram-negative pathogens Ruben Tommasi, PhD Chief Scientific Officer ECCMID 2017 April 24, 2017 Vienna, Austria

More information

Multidrug-Resistant Organisms: How Do We Define them? How do We Stop Them?

Multidrug-Resistant Organisms: How Do We Define them? How do We Stop Them? Multidrug-Resistant Organisms: How Do We Define them? How do We Stop Them? Roberta B. Carey, PhD Centers for Disease Control and Prevention Division of Healthcare Quality Promotion Why worry? MDROs Clinical

More information

Global Antibiotic Research and Development (GARD) Partnership Pasteur Institute DNDi Meeting February 29, 2016

Global Antibiotic Research and Development (GARD) Partnership Pasteur Institute DNDi Meeting February 29, 2016 Global Antibiotic Research and Development (GARD) Partnership Pasteur Institute DNDi Meeting February 29, 2016 Professor Visanu Thamlikitkul, MD Faculty of Medicine Siriraj Hospital, Mahidol University

More information

Antimicrobial stewardship: Quick, don t just do something! Stand there!

Antimicrobial stewardship: Quick, don t just do something! Stand there! Antimicrobial stewardship: Quick, don t just do something! Stand there! Stanley I. Martin, MD, FACP, FIDSA Director, Division of Infectious Diseases Director, Antimicrobial Stewardship Program Geisinger

More information

Northwestern Medicine Central DuPage Hospital Antimicrobial Criteria Updated 11/16/16

Northwestern Medicine Central DuPage Hospital Antimicrobial Criteria Updated 11/16/16 Northwestern Medicine Central DuPage Hospital Antimicrobial Criteria Updated 11/16/16 These criteria are based on national and local susceptibility data as well as Infectious Disease Society of America

More information

These recommendations were approved for use by the Pharmaceutical and Therapeutics Committee, RCWMCH on 1 February 2017.

These recommendations were approved for use by the Pharmaceutical and Therapeutics Committee, RCWMCH on 1 February 2017. Antibiotic regimens for suspected hospital-acquired infection (HAI) outside the Paediatric Intensive Care Unit at Red Cross War Memorial Children s Hospital (RCWMCH) Lead author: Brian Eley Contributing

More information

Addressing the evolving challenge of β-lactamase mediated antimicrobial resistance: ETX2514, a next-generation BLI with potent broadspectrum

Addressing the evolving challenge of β-lactamase mediated antimicrobial resistance: ETX2514, a next-generation BLI with potent broadspectrum Addressing the evolving challenge of β-lactamase mediated antimicrobial resistance: ETX2514, a next-generation BLI with potent broadspectrum activity against Class A, C and D enzymes Alita Miller, PhD

More information

Dr Vivien CHUANG Associate Consultant Infection Control Branch, Centre for Health Protection/ Infectious Disease Control and Training Center,

Dr Vivien CHUANG Associate Consultant Infection Control Branch, Centre for Health Protection/ Infectious Disease Control and Training Center, Dr Vivien CHUANG Associate Consultant Infection Control Branch, Centre for Health Protection/ Infectious Disease Control and Training Center, Hospital Authority NDM-1, which stands for New Delhi Metallo-beta-lactamase-1

More information

ESCMID Online Lecture Library. by author

ESCMID Online Lecture Library. by author Expert rules in susceptibility testing EUCAST-ESGARS-EPASG Educational Workshop Linz, 16 19 September, 2014 Dr. Rafael Cantón Hospital Universitario Ramón y Cajal SERVICIO DE MICROBIOLOGÍA Y PARASITOLOGÍA

More information

Bai-Yi Chen MD. FCCP

Bai-Yi Chen MD. FCCP Treatment strategies for hospitalized versus nonhospitalized CAP patients: Asian perspective Bai-Yi Chen MD. FCCP Professor of Medicine Division of Infectious Disease, Infection Control Team The First

More information

Georgios Meletis, Efstathios Oustas, Christina Botziori, Eleni Kakasi, Asimoula Koteli

Georgios Meletis, Efstathios Oustas, Christina Botziori, Eleni Kakasi, Asimoula Koteli New Microbiologica, 38, 417-421, 2015 Containment of carbapenem resistance rates of Klebsiella pneumoniae and Acinetobacter baumannii in a Greek hospital with a concomitant increase in colistin, gentamicin

More information

Int.J.Curr.Microbiol.App.Sci (2017) 6(3):

Int.J.Curr.Microbiol.App.Sci (2017) 6(3): International Journal of Current Microbiology and Applied Sciences ISSN: 2319-7706 Volume 6 Number 3 (2017) pp. 891-895 Journal homepage: http://www.ijcmas.com Original Research Article https://doi.org/10.20546/ijcmas.2017.603.104

More information

Prevention and control of antimicrobial resistance in healthcare settings: raising awareness about best practices

Prevention and control of antimicrobial resistance in healthcare settings: raising awareness about best practices Prevention and control of antimicrobial resistance in healthcare settings: raising awareness about best practices Dominique L. Monnet, on behalf of ECDC Antimicrobial Resistance and Healthcare-Associated

More information

Antimicrobial Pharmacodynamics

Antimicrobial Pharmacodynamics Antimicrobial Pharmacodynamics November 28, 2007 George P. Allen, Pharm.D. Assistant Professor, Pharmacy Practice OSU College of Pharmacy at OHSU Objectives Become familiar with PD parameters what they

More information

Dr Kamini Walia Indian Council of Medical Research

Dr Kamini Walia Indian Council of Medical Research Dr Kamini Walia Indian Council of Medical Research The apex body in India for the formulation, coordination and promotion of biomedical research under Department of Health Research, Ministry of Health

More information

The CARI Guidelines Caring for Australians with Renal Impairment. 10. Treatment of peritoneal dialysis associated fungal peritonitis

The CARI Guidelines Caring for Australians with Renal Impairment. 10. Treatment of peritoneal dialysis associated fungal peritonitis 10. Treatment of peritoneal dialysis associated fungal peritonitis Date written: February 2003 Final submission: July 2004 Guidelines (Include recommendations based on level I or II evidence) The use of

More information

ICU Volume 14 - Issue 4 - Winter 2014/ Matrix

ICU Volume 14 - Issue 4 - Winter 2014/ Matrix ICU Volume 14 - Issue 4 - Winter 2014/2015 - Matrix Antibiotic Management in the ICU Eleni Patrozou ******@***gmail.com Intensivist - Hygeia Hospital, Athens, Greece Infectious Diseases Division - Alpert

More information

FIS Resistance Surveillance: The UK Landscape. Alasdair MacGowan Chair BSAC Working Party on Antimicrobial Resistance Surveillance

FIS Resistance Surveillance: The UK Landscape. Alasdair MacGowan Chair BSAC Working Party on Antimicrobial Resistance Surveillance FIS 2013 Resistance Surveillance: The UK Landscape Alasdair MacGowan Chair BSAC Working Party on Antimicrobial Resistance Surveillance A statement of the obvious Good quality surveillance data on resistant

More information

(DRAFT) RECOMMENDATIONS FOR THE CONTROL OF MULTI-DRUG RESISTANT GRAM-NEGATIVES: CARBAPENEM RESISTANT ENTEROBACTERIACEAE

(DRAFT) RECOMMENDATIONS FOR THE CONTROL OF MULTI-DRUG RESISTANT GRAM-NEGATIVES: CARBAPENEM RESISTANT ENTEROBACTERIACEAE (DRAFT) RECOMMENDATIONS FOR THE CONTROL OF MULTI-DRUG RESISTANT GRAM-NEGATIVES: CARBAPENEM RESISTANT ENTEROBACTERIACEAE John Ferguson (Hunter New England, NSW) on behalf of MRGN Task Force Acknowledgement

More information

Management of hospital-acquired acquired pneumonia in the Asian Pacific region

Management of hospital-acquired acquired pneumonia in the Asian Pacific region Management of hospital-acquired acquired pneumonia in the Asian Pacific region Jae-Hoon Song, MD, PhD Samsung Medical Center Asian Network for Surveillance of Resistant Pathogens (ANSORP) Asian-Pacific

More information

EDUCATIONAL COMMENTARY THE RISE OF CARBAPENEM-RESISTANT ENTEROBACTERIACEAE

EDUCATIONAL COMMENTARY THE RISE OF CARBAPENEM-RESISTANT ENTEROBACTERIACEAE ENTEROBACTERIACEAE Educational commentary is provided through our affiliation with the American Society for Clinical Pathology (ASCP). To obtain FREE CME/CMLE credits click on Earn CE Credits under Continuing

More information

Why should we care about multi-resistant bacteria? Clinical impact and

Why should we care about multi-resistant bacteria? Clinical impact and Why should we care about multi-resistant bacteria? Clinical impact and public health implications Prof. Stephan Harbarth Infection Control Program Geneva, Switzerland and Ebola (in 2014/2015) Increased

More information

Evaluating the Role of MRSA Nasal Swabs

Evaluating the Role of MRSA Nasal Swabs Evaluating the Role of MRSA Nasal Swabs Josh Arnold, PharmD PGY1 Pharmacy Resident Pharmacy Grand Rounds February 28, 2017 2016 MFMER slide-1 Objectives Identify the pathophysiology of MRSA nasal colonization

More information

The Treatment of Resistant Bacterial Infection in Children

The Treatment of Resistant Bacterial Infection in Children The Treatment of Resistant Bacterial Infection in Children Andrew Whitelaw Division of Medical Microbiology, University of Stellenbosch & NHLS South African Antibiotic Stewardship Programme SAPA/SAAPS

More information

Pharmacokinetic & Pharmadynamic of Once Daily Aminoglycosides (ODA) and their Monitoring. Janis Chan Pharmacist, UCH 2008

Pharmacokinetic & Pharmadynamic of Once Daily Aminoglycosides (ODA) and their Monitoring. Janis Chan Pharmacist, UCH 2008 Pharmacokinetic & Pharmadynamic of Once Daily Aminoglycosides (ODA) and their Monitoring Janis Chan Pharmacist, UCH 25-4-2008 2008 Aminoglycosides (AG) 1. Gentamicin 2. Amikacin 3. Streptomycin 4. Neomycin

More information

Inspired by Children

Inspired by Children Complexities in the early recognition and treatment of meningitis and septicaemia: The unstoppable force of sepsis hitting the immovable object of antibiotic resistance? Inspired by Children Decreasing

More information

Antibiotic Abyss. Discussion Points. MRSA Treatment Guidelines

Antibiotic Abyss. Discussion Points. MRSA Treatment Guidelines Antibiotic Abyss Fredrick M. Abrahamian, D.O., FACEP, FIDSA Professor of Medicine UCLA School of Medicine Director of Education Department of Emergency Medicine Olive View-UCLA Medical Center Sylmar, California

More information

Epidemiology and Economics of Antibiotic Resistance

Epidemiology and Economics of Antibiotic Resistance Epidemiology and Economics of Antibiotic Resistance Eili Y. Klein February 17, 2016 Health Watch USA Meeting I. The burden of antibiotic resistance is a growing global threat, but hard numbers are lacking

More information

Pharmacist Coordinated Antimicrobial Therapy: OPAT and Transitions of Care

Pharmacist Coordinated Antimicrobial Therapy: OPAT and Transitions of Care Pharmacist Coordinated Antimicrobial Therapy: OPAT and Transitions of Care Jennifer McCann, PharmD, BCCCP State Director of Clinical Pharmacy Services St. Vincent Health Indiana Conflicts of Interest No

More information

NUOVE IPOTESI e MODELLI di STEWARDSHIP

NUOVE IPOTESI e MODELLI di STEWARDSHIP Esperienze di successo di antimicrobial stewardship Bologna, 18 novembre 2014 NUOVE IPOTESI e MODELLI di STEWARDSHIP Pierluigi Viale Clinica di Malattie Infettive Policlinico S. Orsola Malpighi Interventions

More information

MAGNITUDE OF ANTIMICROBIAL USE. Antimicrobial Stewardship in Acute and Long Term Healthcare Facilities: Design, Implementation and Challenges

MAGNITUDE OF ANTIMICROBIAL USE. Antimicrobial Stewardship in Acute and Long Term Healthcare Facilities: Design, Implementation and Challenges Antimicrobial Stewardship in Acute and Long Term Healthcare Facilities: Design, Implementation and Challenges John A. Jernigan, MD, MS Division of Healthcare Quality Promotion Centers for Disease Control

More information

48 th Annual Meeting. IDWeek and ICAAC: The Cliffs Notes Version. Skin and Soft Tissue Infections. Skin and Soft Tissue Infections.

48 th Annual Meeting. IDWeek and ICAAC: The Cliffs Notes Version. Skin and Soft Tissue Infections. Skin and Soft Tissue Infections. 48 th Annual Meeting IDWeek and ICAAC: The Cliffs Notes Version Yanina Pasikhova Pharm.D., BCPS-AQ ID, AAHIVP Infectious Diseases Pharmacist Moffitt Cancer Center Navigating the Oceans of Opportunity Skin

More information

Antimicrobial Stewardship Program: Local Experience

Antimicrobial Stewardship Program: Local Experience Antimicrobial Stewardship Program: Local Experience Dr. WU Tak Chiu Associate Consultant Division of Infectious Diseases Department of Medicine Queen Elizabeth Hospital 18th January 2011 QUEEN ELIZABETH

More information

Non-Susceptibility of Bacterial Pathogens Causing Hospital-Onset Pneumonia UK and Ireland,

Non-Susceptibility of Bacterial Pathogens Causing Hospital-Onset Pneumonia UK and Ireland, Non-Susceptibility of Bacterial Pathogens Causing Hospital-Onset Pneumonia UK and Ireland, 2008-2016 Alicia Russell Federation of Infection Societies conference 14 th November 2018 alisia_russell BSAC

More information

CURRICULUM VITAE. Suzane Silbert

CURRICULUM VITAE. Suzane Silbert CURRICULUM VITAE Suzane Silbert, PhD 1. PERSONAL DATA Name: Suzane Silbert Sex: Female Date of Birth: October 27, 1968 Place of Birth: Porto Alegre, Brazil Marital Status: Married E-mail addresses: ssilbert@tgh.org

More information

Antibiotics 201: Gramnegatives

Antibiotics 201: Gramnegatives Antibiotics 201: Gramnegatives B. Joseph Guglielmo, Pharm.D. Professor and Dean School of Pharmacy University of California San Francisco Disclosures No potential conflicts of interest. 1 A 77 year old

More information

Unasyn alternative if penicillin allergic

Unasyn alternative if penicillin allergic Unasyn alternative if penicillin allergic The following guidelines have been developed to assist physicians with the appropriate selection of prophylactic and empiric antibiotic therapy for potential and.

More information

Host, Syndrome, Bug, Drug: Introducing 2 Frameworks to Approach Infectious Diseases Cases with an Antimicrobial Stewardship Focus

Host, Syndrome, Bug, Drug: Introducing 2 Frameworks to Approach Infectious Diseases Cases with an Antimicrobial Stewardship Focus Host, Syndrome, Bug, Drug: Introducing 2 Frameworks to Approach Infectious Diseases Cases with an Antimicrobial Stewardship Focus Montana ACP Meeting 2018 September 8, 2018 Staci Lee, MD, MEHP Billings

More information

Antibiotico resistenza in clinica

Antibiotico resistenza in clinica Dr Bruno Viaggi Dipartimento di Anestesia SOD NeuroAnestesia e Rianimazione CTO AOUC Antibiotico resistenza in clinica Dichiarazione su potenziali conflitti di interesse Consulenze, partecipazione advisory

More information

New Antibiotics for MRSA

New Antibiotics for MRSA New Antibiotics for MRSA Faculty Warren S. Joseph, DPM, FIDSA Consultant, Lower Extremity Infectious Diseases Roxborough Memorial Hospital Philadelphia, Pennsylvania Faculty Disclosure Dr. Joseph: Speaker

More information

Antibiotic Prophylaxis in Spinal Surgery Antibiotic Guidelines. Contents

Antibiotic Prophylaxis in Spinal Surgery Antibiotic Guidelines. Contents Antibiotic Prophylaxis in Spinal Antibiotic Guidelines Classification: Clinical Guideline Lead Author: Antibiotic Steering Committee Additional author(s): Authors Division: DCSS & Tertiary Medicine Unique

More information

UCSF guideline for management of suspected hospital-acquired or ventilatoracquired pneumonia in adult patients

UCSF guideline for management of suspected hospital-acquired or ventilatoracquired pneumonia in adult patients Background/methods: UCSF guideline for management of suspected hospital-acquired or ventilatoracquired pneumonia in adult patients This guideline establishes evidence-based consensus standards for management

More information

Collecting and Interpreting Stewardship Data: Breakout Session

Collecting and Interpreting Stewardship Data: Breakout Session Collecting and Interpreting Stewardship Data: Breakout Session Michael S. Calderwood, MD, MPH Regional Hospital Epidemiologist, Dartmouth-Hitchcock Medical Center March 20, 2019 None Disclosures Outline

More information

Combating Drug-Resistant Infections Globally. Company Presentation

Combating Drug-Resistant Infections Globally. Company Presentation Combating Drug-Resistant Infections Globally Company Presentation Forward-Looking Statements and Other Important Cautions Any statement in this presentation about our future expectations, plans and prospects,

More information